News | August 08, 2022
Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
Pawar also unveiled the India Family Planning 2030 vision document and launched the Medical Eligibility Criteria (MEC) Wheel Application, E-Module of Family Planning Logistics Management System (FPLMIS) and Digital Archive on Family Planning under the category of Digital Intervention.
Biopharma and CROs to benefit from simplified access to global research sites
The Award reinforces Cadila’s digital initiatives which is backed by innovation, research & development and robust frameworks.
Merck’s first microbiology application and training lab in India
The funds raised in the seed round will be used for research and development of Shri Chyawan Ayurved Product
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
PM congratulates citizens on crossing the 200 crore milestone of Covid vaccination drive
Subscribe To Our Newsletter & Stay Updated
